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The diagnostic gap for rare neurodegenerative diseases is still considerable, despite continuous advances in gene identification. Many
novelMendelian genes have only been identified in a few families worldwide. Herewe report the identification of an autosomal-dominant
gene for hereditary spastic paraplegia (HSP) in 10 families that are of diverse geographic origin and whose affected members all carry
unique truncating changes in a circumscript region of UBAP1 (ubiquitin-associated protein 1). HSP is a neurodegenerative disease charac-
terized by progressive lower-limb spasticity and weakness, as well as frequent bladder dysfunction. At least 40% of affected persons are
currently undiagnosed after exome sequencing. We identified pathological truncating variants in UBAP1 in affected persons from Iran,
USA, Germany, Canada, Spain, and Bulgarian Roma. The genetic support ranges from linkage in the largest family (LOD ¼ 8.3) to three
confirmed de novo mutations. We show that mRNA in the fibroblasts of affected individuals escapes nonsense-mediated decay and thus
leads to the expression of truncated proteins; in addition, concentrations of the full-length protein are reduced in comparison to those
in controls. This suggests either a dominant-negative effect or haploinsufficiency.UBAP1 links endosomal trafficking to the ubiquitination
machinery pathways that have been previously implicated in HSPs, and UBAP1 provides a bridge toward a more unified pathophysiology.Hereditary spastic paraplegia (HSP) represents a group of
genetically highly heterogeneous rare inherited neurode-
generative diseases, which are characterized by the patho-
logical hallmark of a length-dependent degeneration of
corticospinal-tract axons (see GeneReviews in Web Re-
sources).1 Clinically, HSPs are marked by progressive
spastic paraparesis, although the clinical presentation en-
compasses a wide spectrum of phenotypes. In pure forms
of HSP, progressive spasticity and weakness in the lower ex-
tremities are the main features. In complex forms of HSP,
additional clinical symptoms include cataracts, ataxia,
epilepsy, cognitive impairment, peripheral neuropathy,
optic neuropathy, and deafness (see GeneReviews in Web
Resources).1 The prevalence of HSP has been estimated
to be 1.3–9.6 in 100,000 (see GeneReviews in Web1Persian BayanGene Research and Training Center, Shiraz, Iran; 2John P. Hus
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Tübingen 72706, Germany; 7Neurogenetics Group Instituto de Investigación Sa
8The Genesis Project foundation Miami, FL 33136, USA; 9Department of Biolog
tee, Shiraz University of Medical Sciences, Shiraz, Iran; 11Center for Therapeut
versity of Miami, Miami, FL 33136 USA; 12Institute of Human Genetics Univers
of Bonn, Bonn 53113, Germany; 14Department of Neurology, Medical Univer
chology, New Bulgarian University, Sofia 1618, Bulgaria; 16Department of Neu
Genetics and Applied Genomics, University of Tübingen, Tübingen 72706, Ger
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 2019 American Society of Human Genetics.Resources).1,2 Thus far, at least 58 genes have been reported
to cause HSP in a Mendelian fashion.3 Yet approximately
40% of affected persons are still not diagnosed even after
whole-exome sequencing (WES). Furthermore, many of
the genes reported in recent years have only been described
in a few families.4
In an effort to further close this diagnostic gap in HSP, we
have gathered a highly diverse sample of 10 families from six
countries (Iran,1;USA,1;Germany, 4;Canada, 1;Bulgaria, 2;
and Spain, 1). Prior to the initiation of this study, all partici-
pating affected individuals gave informed consent in agree-
ment with each institutional review board. In one family of
Persian origin, family 1,wewere able to genetically ascertain
a total of 14 affected individuals from three generations
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übingen 72076, Germany; 6German Center for Neurodegenerative Diseases,
nitaria, Hospital Clı́nico de Santiago, Santiago de Compostela 15706, Spain;
y University of Miami, Miami, FL 33136, USA; 10Student Research Commit-
ic Innovation and Department of Psychiatry and Behavioral Sciences, Uni-
ity of Bonn, Bonn 53113, Germany; 13Department of Neurology, University
sity-Sofia, Sofia 1431, Bulgaria; 15Department of Cognitive Science and Psy-
rology, Medical University-Sofia, Sofia 1431, Bulgaria; 17Institute of Medical
many; 18Centre for Rare Diseases, University of Tübingen, Tübingen 72706,
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Figure 1. Pedigrees of HSP-Affected Families with UBAP1 Truncations
All pedigrees suggest an autosomal-dominant or a de novo Mendelian trait. HSP-affected individuals are marked by filled symbols; indi-
viduals with unclear affection status are marked by a questionmark. ‘‘mut’’ depicts the presence of a causative allele. Sanger traces exem-
plify the confirmation of variants detected via next-generation sequencing. The penetrance of truncating UBAP1 variants is reduced:
individual F5-III.2 was subjectively unaffected at age 14 but showed brisk reflexes of lower limbs, indicating potential dysfunction of
the corticospinal tract. The 80-year-old grandfather of the index case in family 9 (F9-III.1) was unfortunately not available for a neuro-
logical examination but was reported to be in good health and without any indication of a gait disturbance.analysis at the SPG4 locuswere unremarkable. Subsequently,
WES was performed in two affected individuals (V.1 and
V.15). Bioinformatics analysis of the sequencing data used
standard tools, including BWA aligner,5 FreeBayes,5 GATK,6
and GENESIS.7 Only non-synonymous variants with a mi-
nor-allele frequency of less than 0.0001 in gnomAD and in
our in-house Iranian variant database (BayanGene; http://
www.bayangene.com) of 1,500 exomes were further consid-
ered. Two heterozygous variants remained in SVEP1
(chr9: 113137668; rs373655861; p.Thr3527Met hg19
[c.10580C>T]; GenBank: NM_153366.3) and UBAP1 (chr9:
34241270; GenBank: NM_016525.4: c.436_437insTGAG
[p.Ser146Metfs*14]), respectively. The SVEP1 variant was
ruled out by segregation studies involving Sanger
sequencing of the entire pedigree. Thus, after confirmation
of complete segregation, the truncating frameshift
variant in ubiquitin-associated protein 1 (UBAP1) was
considered as the causative allele in family 1 (Figure 1).
This frameshift variant was not present in ExAC, gnomAD,
GENESIS, nor in 1,500 Iranian genomes. It is predicted
to truncate the protein at residue 158 out of 502
amino acids (GenBank: NM_016525.4). By including the
Sanger-confirmed affected and unaffected participants
(Figure 1), we performed parametric two-point linkage anal-
ysis by using the LINKAGE program, which rendered a two-
point LOD score of 8.25 at the position of the UBAP1
insertion.768 The American Journal of Human Genetics 104, 767–773, April 4,We then searched the GENESIS database for additional
families with UBAP1 variants. GENESIS contains more
than 3,000 exomes and genomes from affected persons
with HSP and related disorders.7 We filtered for non-
synonymous and truncating variants under an auto-
somal-dominant model with minor-allele frequency in
gnomAD < 0.0001 and a minimum sequencing depth
of 10 reads. We identified seven additional HSP families,
all carrying truncating variants in UBAP1 (Table 1). In
addition, predictively truncating UBAP1 variants were
prioritized in two families (9 and 10) who underwent
diagnostic exome sequencing at the University of Tue-
bingen. The detection of truncating alleles in all families
is especially remarkable when one considers the almost
complete constraint of UBAP1 for loss-of-function (trun-
cating) variation in the 120,000 chromosomes in both
ExAC and gnomAD, pLi ¼ 0.95 and 0.92, respectively.8
We calculated the probability of significant enrichment
of truncating variations in UBAP1 in our HSP dataset
compared to ExAC. In the GENESIS dataset we found
seven such variants in a cohort of 567 HSP samples
versus 0 truncating variants in 60,000 ExAC samples
(p ¼ 6.187 3 1015 by Fisher test. Odds ratio ¼ infinity).
Five truncating variants were reported in the 246,000
chromosomes in gnomAD, but none fell within the spe-
cific gene region containing the variants reported in
this study.2019
Table 1. Detailed Genomic Locations of Detected Pathogenic Variants
Isoform 1 (GenBank: NM_016525.4)
Expressed in Neurons
Isoform 4 (GenBank: NM_001171201.1)
Canonical According to NCBI
Family ID Genome Assembly (hg19) cDNA Protein Protein
1 chr9: 34241459–34241460 c.436_437insTGAG p.Ser146Metfs*14 p.Ser210Metfs*14
2 chr9: 34241449–34241450 c.426_427delGA p.Lys143Serfs*15 p.Lys207Serfs*15
3 chr9: 34241405–34241405 c.382del p.Ser128Alafs*23 p.Ser192Alafs*23
4 chr9: 34241384–34241384 c.361dupC p.Leu121Profs*18 p.Leu185Profs*18
5 chr9: 34241396–34241396 c.373C > T p.Gln125* p.Gln161*
6 chr9: 34241396–34241396 c.373C > T p.Gln125* p.Gln161*
7 chr9: 34241309–34241313 c.286_290dupCCAGA p.Glu97Aspfs*8 p.Glu161Aspfs*8
8 chr9: 34241318–34241318 c.295dupG p.Asp99Glyfs*2 p.Asp163Glyfs*2
9 chr9: 34249784–34249784 c.1091delC p.Pro364Leufs*50 p.Pro428Leufs*50
10 chr9: 34241449–34241450 c.426_427delGA p.Lys143Serfs*15 p.Lys207Serfs*15
We refer to isoform 1 throughout the text.All additional variants and their segregation with disease
in the additional families were confirmed by Sanger
sequencing. On the basis of transcript GenBank:
NM_016525.4, the identified variants were as follows
(Table 1 and Figure 1): families 2 and 10 from Germany,
c.426_427delGA ( p.Lys143Serfs*15); family 3 fromCanada,
c.382del (p.Ser128Alafs*23); family4 fromSpain, c.361dupC
(p.Leu121Profs*18); families 5 and 6 from Bulgaria (Roma
ethnicity), c.373C>T (p.Gln125*); family 7 from Germany,
c.286_290dupCCAGA (p.Glu97Aspfs*8); family 8 from the
United States, c.295dupG (p.Asp99Glyfs*2), and family 9
from Germany c.1091delC (p.Pro364Leufs*50).
In families 2 and 4, a de novo occurrence of the trun-
cating variant was confirmed (Figure 1). Families 5 and 6
were of self-declared Bulgarian Roma ethnicity and carried
the same p.Gln125* variant, although the two index par-
ticipants are from reportedly unrelated families. Evaluating
the prevalence of this allele in the European Roma popula-
tion and in Gypsy HSP-affected persons will require further
studies.
The first manifesting symptom in all 30 UBAP1 muta-
tion carriers from 10 families for whom detailed clinical
data were available was a progressive spastic-gait disorder
with a median age at onset of 8 years (interquartile range
4–9 years; oldest onset age 26 years; one asymptomatic
mutation carrier (F5-III.2) aged 14 years (detailed clinical
information in Table S1). At the time of examination (me-
dian disease duration 28 years; interquartile range 15–36
years), lower-limb spastic paraparesis was still the most
prominent clinical feature in all affected mutation carriers;
this was accompanied by brisk lower-limb tendon reflexes
(all carriers, including asymptomatic carrier F5-III.2) and
extensor plantar response in all but the youngest affected
individual (F7-IV.6). Although brisk tendon reflexes of
the upper limbs were frequently present (26 of 30; 87%)
significant upper-limb spasticity was seen only in a single
case (1/30; 3%; F4-II.1), consistent with a length-depen-The Amedent axonopathy of the corticospinal tract. Urinary ur-
gency was reported in some cases (11 of 30; 37%), sensory
deficits were absent or mild, and there was no evidence of
peripheral neuropathy. In the majority of families (8/10;
80%), no additional signs or symptoms indicating affec-
tion of neuronal systems other than the corticospinal tract
were seen, and the disease was accordingly classified as
pure HSP. In family 7, however, seven out of nine family
members had features of cerebellar involvement (such fea-
tures included saccadic pursuit, gaze-evoked nystagmus,
dysmetric saccades, and limb ataxia), features also present
in family 9 (F9-II.1), indicating that the cerebellum is
vulnerable to UBAP1 dysfunction at least in some cases.
Overall, truncating UBAP1 mutations are associated
with a predominantly pure early-onset HSP phenotype;
cerebellar involvement seems to be clustered in families
and was observed in 2/10 families. Although there is thus
minimal variation in terms of system involvement across
families carrying UBAP1 mutations, phenotypic variability
exists regarding the progression rate; for example, the dis-
ease progressed rather rapidly and led to early wheelchair
dependency in families 2, 6, and 7 but was almost non-pro-
gressive in family 9 (F9-II.1 is still able to run and walk
unlimited distances after 38 years of disease duration).
Both intrafamilial as well as interfamilial variability are
common or even the norm in HSP.3 A complete under-
standing of the phenotypic spectrum associated with
UBAP1 mutations will require careful clinical evaluation
of additional families carrying UBAP1 mutations.
UBAP1 is a member of the endosomal sorting complex
required for transport -1 (ESCRT-I) complex and a regulator
of vesicular trafficking processes, binds to ubiquitinated
cargo proteins, and is essential for sorting endocytic ubiq-
uitinated cargos into multivesicular bodies (MVBs).9 It
also plays an important role in proteasomal degradation
of ubiquitinated cell-surface proteins, including EGFR
(epidermal growth factor receptor) and BST2 (bonemarrowrican Journal of Human Genetics 104, 767–773, April 4, 2019 769
Figure 2. The Structure of UBAP1 and Mutations Carried by Affected Individuals
(A) Schematic diagram showing all exons and UTRs of UBAP1 on the basis of genemodel GenBank: NM_016525.4. The gray boxes repre-
sent the coding sequence ofUBAP1. All variants occurred in exon 4 ofUBAP1. The UMAprotein domain includes amino acids 17–63, and
two UBAs include amino acids 389–430 and 451–489. All truncations are listed below; the preserving of the UMA domain is clearly de-
picted, but there is loss of the two SOUBA domains.
(B) Immunoblot analysis with an antibody recognizing amino acids 25–75 of UBAP1 shows a notable decrease in the amount of full-
length UBAP1 in fibroblasts of the affected individuals from three different families when these cells are compared to control fibroblasts.
Truncated UBAP1 of the predicted sizes was detected in fibroblasts from affected individuals but not in control fibroblasts.stromal cell antigen 2).9 UBAP1 has two main domains:
The UMA (UBAP1-MVB12-associated) domain in the N-ter-
minal region (17–63 aa), which mediates the association
with the ESCRT-I complex, and a SOUBA (solenoid of
overlapping ubiquitin-associated domains) domain in the
C-terminal region (389–498 aa).9,10 Both domains allow
UBAP1 to act as a molecular bridge connecting the endoso-
mal trafficking pathways to the ubiquitination machinery.
In an effort to decipher the pathophysiology of UBAP1 in
HSP, we noted that all but one of the identified changes fall
within a circumscript area of the protein between Asp 99
and Ser 146; the change in family 9 at Pro364 was the
only outlier (GenBank: NM_016525.4). Interestingly, dis-
ease progression in this family has been dramatically
slower than in the other families: the disease has been
almost stationary over decades (see above), pointing to-
ward a possible genotype-phenotype correlation. Yet, all
changes preserve the UMA domain but cause a loss of the
SOUBA domain.10 It has been shown that mutagenesis of
the SOUBA domain in UBAP1 strongly reduces its interac-770 The American Journal of Human Genetics 104, 767–773, April 4,tion with ubiquitinated proteins (Figure 2).10 To determine
whether the observed truncating variants would lead to
nonsense-medicated mRNA decay and haploinsufficiency,
we evaluated both the RNA and protein expression of
mutant alleles. RT-PCR was performed on RNA extracted
from the fibroblasts of an affected individual, and the
RNA was sequenced by the Sanger method. Surprisingly,
the c.436_437insTGAG was detected in the affected per-
son’s cDNA, indicating escape of nonsense-medicated
mRNA decay (Figure S1). Next, we performed immunoblot
analysis to evaluate both wild-type and potential truncated
mutant UBAP1. Total protein extracts were probed with an
antibody raised against the N-terminal region of UBAP1
(amino acids 25–75), a part of the protein preserved in
mutant UBAP1 proteins. The protein levels measured in
affected individuals were compared with those in four con-
trol fibroblasts and normalized to GAPDH levels. Immuno-
blots showed decreased protein levels of full-length UBAP1
in fibroblasts from affected individuals; in addition, the
truncated protein was detected (Figure 2). The reduced2019
Figure 3. Functional In Vitro and In Vivo Studies of Truncated UBAP1
(A) Immunostaining of U2OS cells transfected with HA-WT-UBAP1 HA-Fs-UBAP1 (p.Leu121Profs*18) and VPS-28-Myc. Both wild-type
and mutant UBAP1 co-localize with VPS28-Myc.
(B) A co-immunoprecipitation assay shows protein-protein interaction between VPS28-Myc and both HA-WT-UBAP1 andHA-Fs-UBAP1.
Ubiquitinated proteins co-immunoprecipitated with HA-WT-UBAP1 but not with HA-Fs-UBAP1. The arrow points to VPS28-Myc, and
the asterisk bellow the arrow indicates the IgG band.
(C) Motor-neuron axons in Tg(olig2TDsRed) zebrafish embryos at 48 hpf. Embryos were injected with CRISPR Cas9 and sgRNAs against
UBAP1; injection was supplemented with human RNA rescue of wild-type or truncated mutant UBAP1. Truncated andmisshaped axons
weremore commonly observed withmutant hRNA rescue (indicated by asterisks). Scale bars represent 50 mm. The phenotypic difference
between treated groups was evaluated by a Fisher exact test. Samples were assigned to either normal or affected categories on the basis
of the presence of truncated andmisshaped axons. The Fisher exact statistic value was determined to be 0.003; the result is significant at
p < 0.005. Statistics describing normal versus affected phenotypes were calculated on the basis of the following sample sizes (number of
embryos observed as having a phenotype). F0 CRISPR þ wild-type hRNA rescue: normal ¼ 11, affected ¼ 1. F0 CRISPR þ mutant hRNA
rescue (family 4, p.Leu121Profs*18), normal ¼ 9, affected ¼ 15.
(D) Quantification of the individualmotor-axon lengths. p values were calculatedwith a one-tailed Student’s t test.: p¼ 0.0008 and n¼ 9
(number of embryos in each experimental group; four axons were measured per embryo).concentrations of the full-length protein in fibroblasts
from affected individuals compared to controls along
with the presence of the truncated protein could poten-
tially lead to haploinsufficiency and/or a dominant-nega-
tive effect. To evaluate the effects of the truncated protein,
we performed site-direct mutagenesis and generated a
plasmid encoding the truncated protein fused to an HA
tag at the N-terminal region. U2OS cells were co-trans-
fected with either wild-type (HA-WT-UBAP1) or a trun-
cated mutant (HA-Fs-UBAP1; p.Leu121Profs*18) together
with its known binding partner VPS28-Myc. Both the
wild-type and the truncated mutant co-localize with
VPS28 (Figure 3A). This suggests that interaction with the
ESCRT-I complex is preserved; however, the lack of the
SOUBA domain, essential for ubiquitin binding, would
be detrimental. Interestingly, overexpression of truncatedThe Ameprotein containing the UMA domain has been shown to
result in a dominant-negative effect by inhibiting HIV-1
budding.10 It is thus possible that expression of the trun-
cated protein in affected persons could cause a domi-
nant-negative effect due to arrest of the ESCRT-complex
without acquiring the ubiquitinated protein cargo.
We performed a co-immunoprecipitation (co-IP) assay to
confirm the interaction between HA-Fs-UBAP1 and VPS28-
Myc. HEK293T cells were co-transfected with VPS28-Myc
and with either HA-WT-UBAP1 or HA-Fs-UBAP1 and
immunoprecipitated with an anti-HA or an anti-Myc anti-
body and analyzed by immunoblot. Our results show that
both wild-type and truncated UBAP1 co-immunoprecipi-
tated with VPS28, confirming protein-protein interaction
(Figure 3B). However, ubiquitinated proteins were co-
immunoprecipitated with the HA-WT-UBAP1 but notrican Journal of Human Genetics 104, 767–773, April 4, 2019 771
with HA-Fs-UBAP1. It has previously been shown that
siRNA depletion of UBAP1 in HeLa cells causes clustering
of early-endosome accumulation of ubiquitinated proteins
and enlargement and clustering of LAMP1-positive late en-
dosomes and lysosomes.9 In fibroblasts of affected persons
carrying UBAP1 mutations, however, none of these
changes could be observed (Figure S2), even after exposure
of cells to stress conditions. It therefore appears unlikely
that loss of one UBAP1 allele results in the gross failure of
multivesicular body sorting.
To investigate the effects of the truncated protein in vivo,
we generated a zebrafish model with UBAP1 knockdown.
We used a transgenic fish with fluorescently labeled moto-
neuron Tg(olig2TDsRed).11 Embryos were injected with
CRISPR Cas9 and sgRNAs against UBAP1 supplemented
with human RNA rescue of either wild-type or truncated
mutant UBAP1. At 48 hours post-fertilization (hpf), em-
bryos were imaged in vivo with a confocal microscope. We
observed significantlymore truncatedandmisshapedaxons
in the mutant rescued embryos than in the wild-type
rescued embryos (Figure 3C). Motoneuron axon lengths in
the truncatedmutantwere significantly (p¼0.0008) shorter
than those of thewild-type (Figure 3D). This result supports
the pathogenic effects of the truncated protein in vivo.
In summary, we present strong genetic evidence that
truncating mutations in UBAP1 cause a relatively frequent
form of HSP. UBAP1 mutations were identified in a large
Iranian kindred as well as in nine additional families
with different ancestral backgrounds, including Bulgarian
Roma, North American of European descent, German,
Spanish, and Quebecois. All available affected persons in
these families carried the respective mutation in UBAP1,
although UBAP1 has a strong loss-of-function constraint
in the 60,000 individuals studied in the ExAC dataset. In
two families we were also able to show a de novo occurrence
of the variants. In our dataset of 567 families affected by
dominant HSP, UBAP1 accounts for 1.2% of cases. Evalu-
ating the full allelic and clinical spectrum in this gene will
require further studies. Because UBAP1 links two cellular
pathways previously involved in HSP, this finding consoli-
dates our current understanding of the pathophysiology
of HSP and points to potential novel drug targets.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.03.001.Acknowledgments
We are thankful to the families who participated in this research.
We thank Els De Vriendt for the excellent technical assistance.
S.Z. and R.S. are supported by National Institutes of Health grant
R01NS072248. The project was further supported by the European
Union’s Horizon 2020 research and innovation program under
grant 779257 (Solve-RD; R.S.) and in the context of the ERA-NET
Cofund action N 643578 by the German Bundesministerium
für Bildung und Forschung (BMBF) (01GM1607) for the E-Rare-3772 The American Journal of Human Genetics 104, 767–773, April 4,network PREPARE (M.S., S.R., and associated partner S.Z.). M.J.S.
was supported by Instituto de Salud Carlos III grant PS09/01830
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